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The cellular attachment and entry of pathogenic microorganisms can be facilitated by the expression of
microbial adhesins that bind fibronectin. We have previously described a Borrelia burgdorferi gene, bbk32, that
encodes a 47-kDa fibronectin-binding protein. In this study, the ligand-binding region of BBK32 from B.
burgdorferi isolate B31 was localized to 32 amino acids. The bbk32 gene was cloned and sequenced from three
additional B. burgdorferi isolates representing different genospecies of B. burgdorferi sensu lato. All four bbk32
genes encoded proteins having fibronectin-binding activity when expressed in Escherichia coli, and the deduced
proteins shared 81 to 91% amino acid sequence identity within the ligand-binding domain. In addition, the
ligand-binding region of BBK32 was found to share sequence homology with a fibronectin-binding peptide
defined for protein F1 of Streptococcus pyogenes. The structural and functional similarity between the ligand-
binding region of BBK32 and the UR region of protein F1 suggests a common mechanism of cellular adhesion
and entry for B. burgdorferi and S. pyogenes.
Lyme disease remains the most prevalent vector-borne in-
fectious disease in North America (17). The spirochete Borrelia
burgdorferi was identified as the etiologic agent of Lyme dis-
ease in 1982 (1). Since then, at least 10 genospecies represent-
ing the complex B. burgdorferi sensu lato have been described
(29). Only the genospecies B. burgdorferi sensu stricto, B. ga-
rinii, and B. afzelii are well established in causing disease in
humans. Recently, however, B. burgdorferi strains resembling
the newly described genospecies B. bissettii were isolated from
Lyme disease patients in Slovenia (27). Human infections with
B. burgdorferi are transmitted by ticks of the Ixodes subgenus.
Once transmitted by tick bite, B. burgdorferi establishes a lo-
calized infection at the site of tick attachment. The spirochetes
migrate in the skin, producing an oval rash termed erythema
migrans in 80% of Lyme disease patients (6). Days to weeks
later, the spirochetes enter the vasculature and disseminate to
multiple tissue and organ sites. At this stage, the patient enters
an early disseminated form of Lyme disease and may present
with carditis, lymphadenopathy, meningitis, and migratory
joint and muscle pain. Despite the presence of a strong host
immune response, B. burgdorferi may persist in the host, and
spirochetes may be isolated from the patient months to years
after transmission. In this late stage of Lyme disease, the pa-
tient’s clinical manifestations may include cutaneous, muscu-
loskeletal, and neurologic involvement. While early interven-
tion with antibiotics is generally efficacious, this late form of
Lyme disease may be more refractory to treatment (26).
The mechanisms by which B. burgdorferi invades and colo-
nizes the host are poorly understood. For many bacterial
pathogens, the initial step in host colonization involves the
expression of adhesive molecules that mediate bacterial adher-
ence to cells or to the extracellular matrix (20, 30). The capac-
ity of B. burgdorferi to bind a wide variety of cells and extra-
cellular matrix components indicates that these organisms may
also express adhesive molecules (24). A common feature of
several pathogenic bacteria, most notably Staphylococcus au-
reus and streptococci, is the expression of adhesins that bind
fibronectin (10). Fibronectin is a large, dimeric glycoprotein
that is produced by a broad range of cell types (22). It exists as
a soluble molecule in body fluids and as an insoluble compo-
nent of cell membranes and the extracellular matrix. Structur-
ally, fibronectin is a mosaic protein composed of three types of
protein modules that are organized into distinct functional
domains. Through these functional domains, fibronectin can
interact with a variety of macromolecules including fibrin, hep-
arin, collagen, and integrins. Many of these functional domains
are also targeted by adhesins expressed by pathogenic micro-
organisms.
Borrelia species also express adhesins that bind fibronectin
(7, 13, 21, 28). We have previously reported on the identifica-
tion of a gene, bbk32, which encodes a 47-kDa fibronectin-
binding adhesin expressed by B. burgdorferi isolate B31 (21).
BBK32 was localized to the outer surface of isolate B31, and
the adhesin was found to interact specifically with the collagen-
binding domain of fibronectin. The ability of recombinant
BBK32 to inhibit binding of isolate B31 to immobilized fi-
bronectin was also demonstrated. These results indicated that
BBK32 is the primary fibronectin-binding adhesin expressed by
B. burgdorferi.
In this study, we extended these earlier observations by map-
ping the ligand-binding region of BBK32 from B. burgdorferi
isolate B31. In addition, we cloned the bbk32 gene from four
isolates representing different B. burgdorferi genospecies into
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Escherichia coli, and determined the degree of sequence con-
servation and functional activity of the expressed proteins.
Mapping the fibronectin-binding Region of BBK32. The
minimal region of BBK32 required to bind fibronectin was
localized by creating a bbk32 gene fragment library using the
Novatope system (Novagen, Madison, Wis.) and screening the
library by ligand blotting. The bbk32 gene was amplified from
B. burgdorferi isolate B31 as previously described (21). The
amplicon was purified using QIAquick spin columns (Qiagen,
Valencia, Calif.), and 5 mg of bbk32 was digested with bovine
pancreatic DNase I in 50 mM Tris-HCl (pH 7.5)–0.05 mg of
bovine serum albumin/ml–10 mM MnCl2. The DNA fragments
were separated on a 2% NuSieve agarose gel (FMC Bioprod-
ucts, Rockland, Maine); the 50- to 150-bp fragments were
excised from the gel and purified using QIAquick spin col-
umns. Blunt ends were created by treatment of the DNA
fragments with T4 DNA polymerase. A 39 adenosine overhang
was then added by Tth polymerase, and the DNA fragments
were ligated into the Novagen pScreen T vector, a pET vector
derivative possessing a T-cloning site upstream of a T7 gene 10
fusion partner. The bbk32 gene fragment library was con-
structed by transforming Novablue (DE3) competent E. coli
(Novagen) with the ligation mixture and selecting for transfor-
mants by plating the bacteria on Luria-Bertani (LB) agar
plates containing 50 mg of carbenicillin/ml. Transformants
were transferred to nitrocellulose membranes, lysed with chlo-
roform vapors, and denatured with 20 mM Tris (pH 8.0)–6 M
urea–0.5 M NaCl. For ligand blotting, the membranes were
washed extensively with 25 mM Tris (pH 7.5)–150 mM NaCl–
0.05% Tween 20 (TTBS), blocked with 3% bovine serum al-
bumin, and probed for 1 h with a 1:30,000 dilution of alkaline
phosphatase-labeled human fibronectin as previously de-
scribed (21). After the membranes were washed with TTBS,
bound fibronectin was detected by immersion of the mem-
branes in a solution of 5-bromo-4-chloro-3-indolylphosphate–
nitroblue tetrazolium (Kirkegaard & Perry Laboratories,
Gaithersburg, Md.). Following this initial screening of the
bbk32 gene fragment library, the fibronectin-binding activity of
each positive colony was confirmed by a second round of ligand
blotting (data not shown).
Seventeen colonies expressing fibronectin-binding activity by
ligand blotting were selected for DNA sequence analysis.
Plasmid DNA was purified from each of the 17 clones using
QIAquick spin columns, and the insert DNA was sequenced by
dye terminator cycle sequencing on an ABI 373 sequencer (PE
Biosystems, Foster City, Calif.). Vector-specific primers, T7
terminator, and STAG (Novagen) were used to sequence both
strands of the insert DNA. Among the 17 clones expressing
fibronectin-binding activity, the smallest bbk32 insert encoded
amino acids 131 to 167 (AA 131-167 construct). Nucleic acid
sequence from a second clone encompassed amino acids 105 to
162 of BBK32 (AA 105-162 construct). The sequence overlap
between these two clones suggested that amino acids 131 to
162 of BBK32 were sufficient to mediate fibronectin binding.
All 17 clones possessed nucleic acid sequence encoding this
segment of BBK32, indicating that this region is likely the
principal fibronectin-binding domain of BBK32.
To further delimit the ligand-binding region of BBK32, we
amplified, cloned, and expressed the segments of bbk32 encod-
ing amino acids 131 to 162, 136 to 162, and 131 to 157 (AA
131-162, AA 136-162, and AA 131-157 constructs) and evalu-
ated the fibronectin-binding activities of these clones by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and ligand blotting. The primers used to amplify these
fragments of bbk32 are listed in Table 1. The amplification
products were ligated into the pScreen T vector, and Novablue
(DE3) competent E. coli were transformed with each con-
struct. Transformants were selected on LB agar plates supple-
mented with carbenicillin (50 mg/ml), and E. coli clones pos-
sessing the desired fragment of bbk32 were verified by DNA
sequencing as described above. The clones were subcultured to
LB broth for 8 h, and recombinant protein expression was
induced for 2 h by the addition of isopropylthiogalactoside to
final concentration of 0.3 mM. The bacteria were harvested by
centrifugation and lysed in SDS-PAGE sample buffer, and
proteins were resolved on a 12% polyacrylamide gel. Following
electrophoretic transfer of the proteins to a nitrocellulose
membrane, ligand blotting was performed as described earlier.
Using the pScreen T-vector expression system, the cloned
DNA is expressed as a peptide fused to a 37-kDa vector-
derived peptide. As shown in Fig. 1A, expression of the various
pScreen/bbk32 constructs in E. coli resulted in the production
of recombinant proteins ranging in size from 48 to 54 kDa.
With the exception of the AA 105-162 construct, the apparent
molecular weight of the recombinant protein exceeded the
molecular weight predicted for each construct. A similar ob-
servation has been made for recombinant proteins derived
from different streptococcal and staphylococcal fibronectin-
binding proteins (11). The AA 131-162 construct produced a
50-kDa protein that bound fibronectin, as demonstrated by
SDS-PAGE and ligand blotting (Fig. 1). However, the level of
fibronectin-binding activity displayed by this clone was much
lower than those of the AA 131-167 and AA 105-162 con-
structs. Furthermore, this fibronectin-binding band appears to
have migrated slightly faster than would be anticipated from
the corresponding Coomassie blue-stained gel. Deletion of five
amino acids from either the N-terminal (AA 136-162 con-
struct) or C-terminal (AA 131-157 construct) end of amino
acids 131 to 162 completely abolished fibronectin-binding ac-
tivity (Fig. 1). Little or no fibronectin-binding activity was as-
sociated with an E. coli clone transformed with pScreen con-
taining no insert DNA (Fig. 1, Vector Only lane). These results
indicate that amino acids 131 to 162, QGSLNSLSGESG
ELEEPIESNEIDLTIDSDLR, defined the fibronectin-binding
TABLE 1. Oligonucleotide primers used for amplification of bbk32 gene fragments
BBK32 construct Forward primer Reverse primer
AA 131-162 59-CAAGGAAGTTTAAATTCCCT 59-CCTTAAATCAGAATCTATAG
AA 131-157 59-CAAGGAAGTTTAAATTCCCT 59-TATAGTAAGATCAATTTC
AA 136-162 59-TCCCTTAGCGGTGAAAGT 59-CCTTAAATCAGAATCTATAG
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region of BBK32. A striking feature of this sequence is the
relatively high number of acidic amino acid residues. This
sequence characteristic has been noted for other bacterial fi-
bronectin-binding proteins (11).
Functional activity and sequence analysis of BBK32 from
different genospecies of B. burgdorferi sensu lato. Having de-
fined the ligand-binding region of BBK32, we sought to estab-
lish whether BBK32 is functionally and genetically conserved
among isolates of B. burgdorferi sensu lato. To this end, we
cloned and expressed bbk32 from four isolates representing
different genospecies of B. burgdorferi: isolate B31, B. burgdor-
feri sensu stricto; isolate IP90, B. garinii; isolate ACA1, B.
afzelii; and isolate DN127, B. bissettii. As previously described
for isolate B31 (21), the bbk32 gene was amplified from each
isolate and cloned into the pMalc2 expression vector (New
England Biolabs, Inc., Beverly, Mass.), in which the gene of
interest is expressed as a peptide fused to a 42-kDa vector-
derived peptide. In each case, the transformation of E. coli
with a bbk32 construct derived from either B31, IP90, ACA1,
or DN127 resulted in the expression of an 80-kDa recombinant
fusion protein that bound fibronectin, as determined by SDS-
PAGE and ligand blot analysis (Fig. 2). The appearance of
lower-molecular-weight bands having fibronectin-binding ac-
tivity in Fig. 2 likely represents proteolysis of the overexpressed
recombinant proteins. These results demonstrate that each B.
burgdorferi isolate possesses a bbk32 gene that was capable of
encoding a functional protein upon expression in E. coli. In
contrast, when spirochetal lysates of B31, IP90, ACA1, and
DN127 were tested by SDS-PAGE and ligand blotting for
fibronectin-binding activity, only two of these four B. burgdor-
feri isolates expressed a fibronectin-binding protein (Fig. 3). As
observed previously (21), isolate B31 expressed relatively high
levels of a 47-kDa fibronectin-binding protein (BBK32),
whereas ACA1 fibronectin-binding activity was visible as a
faint band of 45 kDa. No fibronectin-binding activity was de-
tected for the IP90 and DN127 lysates by ligand blotting. The
lack of fibronectin-binding activity observed for isolates IP90
and DN127, despite the presence in both cases of a bbk32 gene
capable of encoding a functional protein, suggest that bbk32
expression may be tightly regulated during in vitro cultivation
of these isolates.
Next, we evaluated the degree of sequence conservation in
the ligand-binding region of BBK32 by sequencing the cloned
gene from isolates IP90, ACA1, and DN127. For each pMa1c2/
bbk32 construct, three representative clones were sequenced
by dye terminator cycle sequencing using an ABI 373 DNA
FIG. 1. Mapping the ligand-binding region of BBK32. Fragments
of the bbk32 gene from B. burgdorferi isolate B31 were cloned into the
pScreen T vector and expressed as recombinant fusion proteins in E.
coli. Proteins from E. coli lysates were separated on a 12% polyacryl-
amide gel and stained with Coomassie blue (A) or transferred to
a nitrocellulose membrane and probed with alkaline phosphatase-
labeled human fibronectin (B). The BBK32 amino acid sequence ex-
pressed by each clone is indicated above each lane. A clone expressing
the vector-derived peptide of 37 kDa is labeled Vector Only. Sizes of
the molecular weight standards (MWS) are provided in kilodaltons.
FIG. 2. Fibronectin-binding activities of E. coli clones expressing
the bbk32 gene from isolates representing different genospecies of
B. burgdorferi. The bbk32 gene was amplified from each isolate and
cloned into the pMalc2 vector. Expression of the cloned gene results in
a recombinant fusion protein of 80 kDa. Lysates from each E. coli
clone were subjected to SDS-PAGE on a 12% polyacrylamide gel and
stained with Coomassie blue (A) or transferred to nitrocellulose for
ligand blotting with alkaline phosphatase-labeled human fibronectin
(B). The isolate from which bbk32 was derived is indicated above each
lane. The genospecies designation for each isolate is as follows: B31, B.
burgdorferi sensu stricto; IP90, B. garinii; ACA1, B. afzelii; and DN127,
B. bissettii. Expression of the pMalc2 vector in E. coli produces a fusion
protein of 52 kDa (Vector Only). Sizes of the molecular weight mark-
ers (MWS) are provided in kilodaltons.
FIG. 3. Fibronectin-binding activities of isolates representing dif-
ferent B. burgdorferi genospecies. Proteins from the spirochete lysates
were separated by SDS-PAGE on a 12% polyacrylamide gel. The
proteins were detected by staining with Coomassie blue (A) or trans-
ferred to a nitrocellulose membrane for ligand blotting with alka-
line phosphatase-labeled human fibronectin (B). Isolates B31, IP90,
ACA1, and DN127 have been genotyped as B. burgdorferi sensu stricto,
B. garinii, B. afzelii, and B. bissettii, respectively. The weak fibronectin-
binding activity of strain ACA1 was evident in the original ligand blot
but may not be clearly visible in photograph (B). Sizes of the molecular
weight markers (MWS) are shown in kilodaltons.
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sequencer. Approximately 90% of the gene sequence predicted
to encode the mature BBK32 protein was sequenced for each
isolate, and the sequences were deposited in GenBank. The
alignment by clustal analysis (Lasergene 99; DNASTAR, Inc.,
Madison, Wis.) of the predicted BBK32 amino acid sequences
from these isolates and isolate B31 revealed sequence identity
ranging from 69 to 90% (amino acids 35 to 337 [data not
shown]). Slightly less variability was observed within the li-
gand-binding region of BBK32 (Fig. 4). Sequence identity for
this segment of BBK32 ranged from 81 to 91% between iso-
lates. Within the ligand-binding region of BBK32, the amino
acid sequence motifs LSGESGEL and IESNEID were con-
served among all four isolates.
A BLAST search of GenBank for sequences homologous to
the BBK32 ligand-binding region from isolate B31 produced a
single match with an in vivo-expressed protein described for B.
burgdorferi sensu stricto isolate N40 (3). The N40 amino acid
sequence was identical to the BBK32 ligand-binding region of
isolate B31, indicating that the N40 homolog may also interact
with fibronectin. As was observed for isolates IP90 and DN127
in our study, N40 does not appear to express bbk32 during
cultivation in vitro. However, bbk32 expression by N40 was
detected following reverse transcription-PCR analyses of tis-
sues from mice experimentally infected with this isolate (3).
Expression of bbk32 has also been detected in skin and joint
tissue biopsies from patients with Lyme disease (4). Despite
variability in bbk32 expression levels among cultivated B. burg-
dorferi isolates, these studies indicate that bbk32 expression
may be upregulated by B. burgdorferi during colonization of the
mammalian host.
We also aligned the BBK32 ligand-binding region from iso-
late B31 with fibronectin-binding motifs described for other
bacterial proteins including fibronectin attachment protein
(23) and antigen 85b (16) from mycobacteria, FnbpA from
Staphylococcus aureus (25), and protein F1 from Streptococcus
pyogenes (18). Among these proteins, only protein F1 from S.
pyogenes shared significant sequence homology with the ligand-
binding region of BBK32. The BBK32 ligand-binding region of
isolate B31 and the UR region of protein F1 shared sequence
identity at 8 of 13 contiguous amino acids: LXGESG
EXEXXXE, where X is a dissimilar amino acid (Fig. 4). The
motif LXGESGE was also conserved among all B. burgdorferi
sensu lato isolates sequenced in our study. Like BBK32, the
UR region of protein F1 interacts with the collagen-binding
domain of fibronectin (18, 21). The sequence homology shared
between the ligand-binding region of BBK32 and the UR re-
gion of protein F1 may dictate the specificity of these proteins
for the collagen-binding domain of fibronectin. A similar mo-
tif, LAGESGET, has also been recognized in the fibronectin-
binding protein, FNZ, from Streptococcus equi subsp. zooepi-
demicus (14). The region of fibronectin bound by this segment
of FNZ awaits localization.
The structural and functional resemblance of BBK32 to the
UR region of protein F1 suggest that BBK32 may provide B.
burgdorferi with a mechanism of host colonization similar to
the role proposed for protein F1 during S. pyogenes infections.
Protein F1 expression has been implicated in the cellular ad-
herence and entry of S. pyogenes (9, 15, 19). Protein F1 may
facilitate S. pyogenes adherence by binding fibronectin depos-
ited on cell surfaces or by interacting with soluble fibronectin,
which in turn binds to cell surface molecules such as integrins.
Ozeri et al. (19) have demonstrated that the indirect interac-
tion of protein F1 with b1 integrins via a fibronectin bridge can
induce internalization of adherent S. pyogenes by the cell. The
cellular uptake of S. pyogenes through the indirect interaction
of protein F1 with integrins may provide this pathogen with a
mechanism of penetrating tissue barriers and establishing deep
tissue infections. Likewise, the ability of BBK32 to bind fi-
bronectin, and indirectly integrins, may provide B. burgdorferi
with a similar mechanism of cellular adherence and entry. The
observation that b1 and b3 integrins may be involved in the
adherence of B. burgdorferi to human cells lends support to this
hypothesis (2). Furthermore, the ability of B. burgdorferi to
invade cultured cells and survive intracellularly has been doc-
umented by electron microscopy, by confocal microscopy, and
by antibiotic protection assays performed with ceftriaxone (5,
8, 12). Despite support from these in vitro studies, the in vivo
capacity of B. burgdorferi to invade and persist within cells has
proven difficult to establish. The potential intracellular exis-
tence of B. burgdorferi, however, may help explain the persis-
tent nature of B. burgdorferi infections and the occasional fail-
ure of antibiotic therapy. We are currently investigating the
role of BBK32 in cell adherence and invasion by expressing
bbk32 in a heterologous host.
Nucleotide sequence accession numbers. The GenBank ac-
cession numbers for the bbk32 sequence from B. burgdorferi
isolates B31, IP90, ACA1, DN127, and N40 are AE000788,
AF213178, AF213179, AF213180, and U82107, respectively.
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